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abstract
One of the milestones in the history of the cardiac surgery is the 
development of extracorporeal circulation, which allowed hundreds 
of thousands of patients under successful open cardiac surgery. It´s 
objective is to maintain the vital organ´s perfusion, provide a bloo-
dless field for surgery, and at the same time, give protection to the 
heart and lungs. Its principle is to bring most or all of the patient’s 
systemic blood, which normally returns to the right atrium, into an 
oxygenator in which oxygen is supplied to the blood and carbon 
dioxide is removed. The arterialized blood is filtered, heated and, 
pumped into the aorta and the systemic arterial system. But this 
continuous blood recirculation through nonendothelial surfaces of 
the perfusion system produces an inflammatory response. Despite 
all the advantages and strategies developed to try to make the most 
physiological condition during the extracorporeal circulation, there 
are still persistent controversies, which we are going to review, as 
well as the inflammatory response produced by the perfusion system, 
and it´s future directions. 
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Introduction
The application of physiologic investigations has lead to such dramatic 
advances in open cardiac surgery that unexpected observations and 
new facts have come from operating rooms and not from experimen-
tal laboratories. [1]
The urgent need for surgical repair in congenital and acquired heart 
disease provided the vigorous and impetus needed to become the 
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artificial heart and lungs machine a reality. This ope-
ned a vast and almost unexplored field for cardiac 
surgeons. [2] 
History
Certainly, one of the milestones in the history of 
the cardiac surgery is the cardiopulmonary bypass 
(CPB). This allowed unimaginable accomplishment, 
previously thought impossible, such as performing 
an open cardiac surgery. A few years later, many 
patients a year undergo successful cardiac surgery 
with excellent clinical outcomes. It is hard to sin-
gle out one investigator or one discovery which 
has made this brave, new world of cardiac surgery 
possible because it is the result of a century long 
brilliant intellectual curiosity. Lasting credit goes to 
the vision and perseverance of Gibbon who deve-
loped the principle of blood filming and reported 
the maintenance of life during clamping of the pul-
monary artery in 1937, the first series of consecu-
tively surviving dogs after total CPB in 1952 and 
the first successful human application on May 18, 
1953, when he repaired an atrial septal defect in 
a young woman totally supported using a pump 
oxygenator. [3, 4] 
C. Walton Lillehei and colleagues, who used a 
method of cross circulation, convincingly demons-
trated that life could be supported by artificial 
means while the heart and lungs were temporarily 
excluded from the circulation. They brought into 
being the modern era of open cardiac surgery.2 
John Kirklin first used a CPB with a pump oxygena-
tor at the Mayo Clinic on March 22, 1955.5
Pump oxygenator for cardiac surgery had to 
await development of modern anesthesia, modern 
surgical methods, and scientific developments such 
as discovery and use of heparin and manufacture 
of biocompatible plastic materials. [6]
The principle of CPB is that most or all of the 
patient’s systemic blood, which normally returns to 
the right atrium, is derived into a device in which 
oxygen is supplied to the blood and carbon dioxide 
is removed. This arterialized blood is pumped from 
the device into the aorta. Complexities of CPB inclu-
de that blood does not naturally circulate through 
nonendothelially-lined channels, contain gaseous 
and particulate emboli, experience nonphysiologic 
shear stresses, absence of any appreciable pulmo-
nary blood flow and minimal pulsatile aortic pres-
sure. [6]
It can be adapted to provide partial or total circu-
latory and respiratory support. Total CPB is when all 
the venous blood returns to the pump oxygenator 
instead of the heart. Partial CPB is when some sys-
temic venous blood returns to the right atrium and 
ventricle, and is pumped into the lungs, then passes 
back into the left heart and pumped into the aorta. 
Components
The components include: venous cannula, reser-
voir, pump, membrane/oxygenator/heat exchanger, 
microfilter-bubble trap, arterial cannula, and the pa-
tient is positioned in between. All the tubing and 
connections must allow the blood flow path smooth 
and uniform, without areas of stenosis, kinking or 
expansion. [7]
Depending on the operation, various suction sys-
tems are used to return blood from the surgical 
field. Aspirated blood passes through a cardiotomy 
reservoir and microfilter before returning to the ve-
nous reservoir. It is recommended, field blood be 
washed in a cell saver system and returned to the 
perfusate as packed red cells. Sites for obtaining 
blood samples and sensors for monitoring pressu-
res, temperatures, oxygen saturation, blood gases, 
and pH are included, as are various safety devices. 
[8]
A separate circuit for administering cardioplegic 
solutions at controlled composition, rate, and tem-
perature is usually included in the system.
Venous Input
Venous blood usually enters the circuit by gravity 
or siphonage into a venous reservoir placed 40 to 
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70 cm below the level of the heart. The amount 
of drainage is determined by central venous pres-
sure; the height differential; resistance in cannulas, 
tubing, and connectors; and absence of air within 
the system. [8]
Venous Reservoir
Serves as a receiving chamber for venous return, 
facilitates gravity drainage, is a venous bubble trap; 
provides a convenient place to add drugs, fluids, or 
blood; and adds storage capacity for the perfusion 
system, that if the venous return is suddenly stop-
ped, the reservoir can provide a continuous perfu-
sion during several seconds. [7]
Oxygenator
Not only regulates the gases tension in the arterial 
blood, but also, is the largest area of foreign sur-
face blood comes into contact with, and therefore 
where the most blood damage occurs. There are 
two types: membrane and bubble oxygenators. 
Membrane oxygenators imitate the natural lung by 
interspersing a thin membrane of either micropo-
rous (0.3- to 0.8-μm pores) between the gas and 
blood phases. Compared to bubble oxygenators, 
membrane oxygenators are safer, produce less par-
ticulate and gaseous microemboli, are less reactive 
to blood elements, and allow superior control of 
blood gases. [9-11]
Arterial partial carbon dioxide pressure (PaCO2) 
is controlled by gas flow, and arterial partial oxygen 
pressure (PaO2) is controlled by the fraction of 
inspired oxygen (FIO2) produced by an air-oxygen 
blender. PaO2 is related to temperature of the 
patient, which is related to oxygen consumption 
(VO2).
Some clinical perfusions for cardiac surgery are 
performed at normothermia (≈37°C) and others 
at various levels of hypothermia: mild (30°C-35°C), 
moderate (25°C-30°C), or deep (<25°C). Therefore, 
it is necessary to consider the strategy for contro-
lling PaCO2 and, indirectly, pH.5
Hypothermia is used in some cases, for exam-
ple, when a complete circulatory arrest is needed, 
because it reduces metabolic activity to the extent 
that available energy stores in the various organs 
maintain cell viability throughout the ischemic pe-
riod of circulatory arrest and thus allow normal 
structure and function to return after reperfusion. 
The patient´s body temperature is the most impor-
tant determinant of the length of safe circulatory 
arrest time.
Heat exchanger
Control the body temperature by heating or coo-
ling blood passing through the perfusion circuit. 
Hypothermia is frequently used during cardiac 
surgery to reduce oxygen demand or to facilitate 
operative exposure by temporary circulatory arrest. 
Gases are more soluble in cold than in warm blood; 
therefore, rapid rewarming of cold blood in the cir-
cuit or body may cause formation of bubble em-
boli.12 Blood is not heated above 40°C to prevent 
denaturation of plasma proteins, and temperature 
differences within the body and perfusion circuit are 
limited to 5 to 10°C to prevent bubble emboli. A 
separate heat exchanger is needed for cardioplegia.
Pumps
There are three types: roller, impeller, and centrifu-
gal. Roller pumps have two rollers 180° apart. Im-
peller uses vanes on a rotating shaft, and centrifugal 
pumps uses three concentric cones. [13]
Roller pump is nearly occlusive, afterload inde-
pendent, Its advantages are: require low prime vo-
lume, low cost, no potential for backflow. Disvad-
ntages are: produce excessive positive and negative 
pressure that can cause tubing rupture, potential 
for massive air embolism, necessary occlusion ad-
justments, requires close supervision. Roller pumps 
are used for sucker systems, and for delivering car-
dioplegia.
Centrifugal pump is nonocclussive, afterload sen-
sitive. Advantages: safe positive and negative pres-
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sure, adapts to venous return, superior for right of 
left heart bypass, preferred for long-term bypass, 
and protects against air embolism. Disadvantages: 
higher cost, potential passive backward flow, and 
require larger priming volume.
arterial Output 
Arterial outflow to the patient is achieved by gene-
rating a large pressure gradient by the pump. The 
most commonly used type of arterial pump is the 
roller pump. It generates a relatively nonpulsatile 
flow and is simple, reliable, and relatively inexpen-
sive. In clinical use, roller pumps are generally set to 
be nearly occlusive. When they are occlusive, trau-
ma to the formed elements in blood is increased; 
when they are too nonocclusive, they are unable 
to maintain the same rate of flow against the wide 
range of resistances (pressure differentials of 30-
300 mmHg) offered by arterial cannula and the 
patient’s systemic vascular resistance.
The arterial line pressure must be continuously 
monitored. When exceeds 250 to 300 mmHg, in-
creases risk of disruption of the arterial line and of 
cavitation in the region of the arterial cannula.
Perfusate solution
Require 1.5-2 L depending upon the preoperative 
hematocrit value. It is a balanced electrolyte solution 
with a near normal pH and an ion content resem-
bling that of the plasma. Before connection to the 
patient, the prime is recirculated to remove air, re-
presents 30-35% of the patient´s blood volume and 
reduces the hematocrit to 2/3 of the preoperative 
value. The use of colloids in the priming solution is 
controversial. [14]
Filter
During CPB the wound and the perfusion circuit 
generate gaseous, biologic and nonbiologic mi-
croemboli particulates. Sources of gas entry include 
stopcocks, sampling and injection sites,15 priming 
solutions, priming procedures, intravenous fluids, 
vents, the cardiotomy reservoir, tears or breaks in 
the perfusion circuit, loose purse-string sutures (es-
pecially during augmented venous return),16 rapid 
warming of cold blood,12 cavitation, oxygenators, 
venous reservoirs with low perfusate levels. [17, 18]
There are many potential sources of microembo-
li. Blood produces emboli related to thrombus for-
mation (clots), fibrin, platelet and platelet-leukocyte 
aggregation, hemolyzed red cells, cellular debris, 
and generation of chylomicrons, fat particles, and 
denatured proteins. [7]
To prevent microemboli formation: membrane 
oxygenator, centrifugal arterial pump, cardiotomy 
reservoir filter, arterial line filter, keep temperature 
differentials <8-10°C, primer with Carbon Dioxide 
flush, prevent air entry into the circuit (snug purse-
string sutures, three way stopcocks on all sampling 
ports, avoid excessive suction on vents), wash blood 
aspirated from surgical field,19 prevent thrombus 
formation with adequate anticoagulation, assess in-
flow cannulation by epiaortic ultrasound imaging, 
consider use of special aortic cannulas with20-22 or 
without baffles or screens to reduce the number of 
atherosclerotic emboli. [23]
Microfilters
The brain receives 14% of the cardiac output and 
is the most sensitive organ for microembolic injury. 
Strategies to selectively reduce microembolism to 
the brain include reducing PaCO2 to cause cere-
bral vasoconstriction; hypothermia; placing aortic 
cannulas downstream to the cerebral vessels; and 
using special aortic cannulas with or without spe-
cial baffles or screens designed to prevent cannula-
produced cerebral atherosclerotic emboli. 
As compared to no filter, studies indicate that all 
commercial filters effectively remove gaseous and 
particulate emboli. Filters cause slight hemolysis and 
tend to trap some platelets; nylon filters may acti-
vate complement.
The need for microfilters in the cardiotomy suc-
tion reservoir is universally accepted, and most com-
InternatIonal archIves of MedIcIne
Section: cardiac tranSplantation
Issn: 1755-7682 
2015
Vol. 8 No. 19
doi: 10.3823/1618
© Under License of Creative Commons Attribution 3.0 License 5
mercial units contain an integrated micropore filter. 
Moreover, as compared to perfusion microemboli, 
surgically induced emboli are more likely to cause 
postoperative neurologic deficits.
Cardiotomy Reservoir 
Here is storage all the blood aspirated from the sur-
gical field for defoaming, filtration before be added 
directly to the perfusate. Represent the major source 
of hemolysis, particulate and gaseous microemboli, 
fat globules, cellular aggregates, platelet injury and 
loss, thrombin generation, and fibrinolysis.24 This 
aspirated blood also goes to the venous reservoir.
Venting 
During CPB, distension of either ventricular (major 
the left ventricle) is injurious when the heart is una-
ble to contract, because increases the O2 demand, 
and therefore is detrimental to the subsequent con-
tractility. 25 During CPB blood escaping atrial or 
venous cannulas, coronary sinus, thebesian veins 
may pass to the right ventricle to the pulmonary 
circulation. This blood plus blood from bronchial 
vessels, and from abnormal sources (foramen ovale 
or ductus) distend the left ventricle unless a vent 
catheter is used. 
Locations used to vent: aortic root (which can 
also be used to administer cardioplegia after the as-
cending aorta is clamped), right superior pulmonary 
vein through the mitral valve into the left ventricle, 
direct venting of the left ventricle at the apex, and 
the main pulmonary artery, which decompresses 
the left atrium since pulmonary veins lack valves. 
[26, 27] 
Cardioplegia
A carrier that could be a crystalloid or preferable 
blood contain K+, Mg2+, infused at temperatures 
around 4-37°C, depending upon surgeon surgeon 
preference. Normothermic cardioplegia must be 
delivered almost continuously to keep the heart 
arrested; cold cardioplegia if infused intermittently 
from 15 to 20 minutes, into the aortic root proxi-
mal to the aortic clamped or retrograde into the 
coronary sinus in order to arrest the heart into 
diastole. Is delivered through a separate perfusion 
system that includes reservoir, heat exchanger, and 
a roller pump. 
Antegrade cardioplegia is administered at 60-100 
mm Hg, allow arrests within 30-60 seconds, delay 
indicates problems with the delivery or unrecogni-
zed aortic valve insufficiency. Retrograde cardio-
plegia delivered at 30-50 mmHg. Higher pressures 
may injure the coronary sinus. Its induction arrest is 
slower from 2-4 min, and may provide inadequate 
protection to the right ventricle. [28, 29]
Determinants of Safe Perfusion
Blood Flow Rate
In normal conditions, cardiac output is determined 
by oxygen consumption, which is approximately 250 
mL/min.30 The flow rate at 35-37°C and hemato-
crit of 25% is 2.4 L/min/m2. Hypothermia reduces 
oxygen consumption by a factor of 0.5 for every 
10°C decrease in temperature. 
There is no evidence from a benefit of pulsatile 
blood flow over nonpulsatile blood flow for short 
or long term CPB. [31]
Mixed venous oxygen saturation (SvO2) assesses 
the relationship between de O2 delivery and its 
consumption. Values below 60% indicate inade-
quate oxygen delivery and a whole body perfu-
sion that is not meeting the patient´s metabolic 
demands. [32]
arterial blood pressure
Is determined by flow rate, blood viscosity (hema-
tocrit), and systemic vascular resistance. It is not 
necessary to pharmacologically manipulate syste-
mic vascular resistance during CPB, unless it is less 
than 40-50 mmHg, when the autoregulation of the 
brain is disrupted, and the cerebral blood flow may 
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decline appreciably, with a concomitant decrease in 
cerebral oxygen consumption. [33-35]
Hematocrit
When the hematocrit is abnormally high, oxygen 
content is high, but the increased viscosity tends to 
decrease microcirculatory blood flow. Hypothermia 
increases blood viscosity; therefore, at low tempe-
ratures, a lower hematocrit is more appropriate 
than at 37°C. Hematocrit of about 20% to 25% 
may be optimal during moderately and deeply 
hypothermic CPB. During rewarming, a higher he-
matocrit may be desirable because of increased 
oxygen demands, and the higher apparent vis-
cosity of a higher hematocrit is appropriate du-
ring normothermia. The ideal hematocrit remains 
controversial. In general, viscosity remains stable 
when percent hematocrit and blood temperature 
are equal (viscosity is constant at hematocrit 37%, 
temperature 37°C, or at hematocrit 20%, tempe-
rature 20°C). [36-38]
Temperature
Hypothermia allows use of lower pump flow rate 
with less hematocrit and blood trauma, protects 
the brain, achieves better myocardial protection 
and protection of other organs than normothermic 
CPB. Systemic hypothermia also provides a margin 
of safety for organ protection. The patient’s body 
temperature is the most important determinant of 
the length of safe circulatory arrest time.
However, the ideal temperature for cardiac sur-
gery is controversial.37 Hypothermia interferes with 
enzyme and organ function, aggravates bleeding, 
increases systemic vascular resistance, delays cardiac 
recovery, increases the risk of cerebral hypothermia. 
[39]
pH Management
Changes in temperature affect acid-base balance, 
which must be monitored and managed during 
deep hypothermia. Management of gas exchange 
during cooling is also controversial. There are two 
strategies, each have advantages and disadvanta-
ges.
The α-stat strategy is based using the pH mea-
sured at 37°C, non temperature-corrected, to 
maintain this ventilation level at any temperatu-
re. It allows the pH to increase during cooling. 
The α-stat strategy results in optimal function of 
a number of important enzyme systems, including 
lactate dehydrogenase, phosphofructokinase, and 
Na+K+ATPase. With this protocol, cerebral blood 
flow is lower, autoregulated and coupled to cere-
bral oxygen demand. 
The pH-stat strategy strives for the same values 
of pH and PaCO2, corrected to the temperature. 
This represents a state of respiratory acidosis and 
hypercarbia. This strategy increases the rate and 
uniformity of brain cooling. Cerebral blood flow in-
creases, and pressure is passive and uncoupled from 
cerebral oxygen demand, but may expose the brain 
to a larger number of microemboli.
At a cellular enzyme level, the α-stat strategy may 
be preferable, but which is preferable in clinical car-
diac surgery in neonates, children, and adults is the 
subject of continued investigation and debate.40 
The α-stat strategy results in a lower PaCO2, which 
may adversely affect cerebral blood flow. This may 
be of particular importance for patients with cya-
notic congenital heart disease for whom low PaCO2 
may result in pulmonary vasodilatation in addition 
to cerebral vasoconstriction. Thus, there can be a 
steal of blood from the cerebral to the pulmonary 
vascular bed. pH-stat management results in supe-
rior neurologic outcome during deep hypothermic 
CPB and hypothermic circulatory arrest in pedia-
tricians.41,42 The pH-stat technique may depress 
cardiac function.
Blood response. Coagulopathy.
All biomaterial surfaces, including heparin-coated 
surfaces, are procoagulant; 43 A nonthromboge-
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nic synthetic surface remains undiscovered, and 
only the endothelial cell is truly nonthrombogenic. 
In normal state, the fluidity and integrity of the 
vascular system are established and maintained 
by equilibrium between procoagulants and anti-
coagulants factors. endothelial cells anticoagulant 
activities include: production of t-PA, heparin sul-
fate, dermatan sulfate, protein S, tissue factor in-
hibitor protein, thrombomodulin, prostacyclin, ni-
tric oxide, and adenosine. When disrupted exhibit 
procoagulant activities: expression of tissue factor, 
production of collagen, elastin, laminin, fibronec-
tin, thrombosopondin, von Willebrand factor, fac-
tor V, platelet activating factor (PAF), factor IXa 
and factor Xa.
During CPB high concentration of heparin is nee-
ded to maintain the fluidity of blood: 3-4 mg/kg ini-
tial doses. Additional heparin is given as needed to 
achieve an ACT of greater than 400 seconds during 
normothermic CPB, and greater than hypothermic 
CPB (< 30°C).
The continuous exposure of heparinized blood to 
the perfusion circuit and to the wound during clini-
cal cardiac surgery produces an intense thrombotic 
stimulus that involves both the extrinsic coagulation 
pathway (tissue factor pathway) in the wound and 
the contact and intrinsic coagulation pathways in 
the perfusion circuit. 
The extrinsic pathway is the major source of 
thrombin generation during CPB. This fact has en-
couraged strategies to reduce the amounts of cir-
culating thrombin during clinical cardiac surgery by 
either discarding wound blood or by only salvaging 
red cells by centrifugation and washing in a cell saver. 
While there is no evidence that heparin-coated cir-
cuits reduce thrombin generation, there is strong 
evidence that discarding wound plasma or limiting 
exposure of circulating blood to the wound does 
reduce the circulating thrombin generation. [44]
Heparin does not directly inhibit coagulation, but 
is a cofactor of antithrombin. Antithrombin primary 
binds thrombin, its action on factor Xa and IXa is 
much slower. Heparin inhibits coagulation at the 
end of the cascade after almost all other coagula-
tion factors have been activated. Thrombin is con-
tinuously generated and circulated despite massive 
doses of heparin in all applications of extracorporeal 
perfusion. [45]
This imperfect anticoagulant permits formation 
of microthrombi in the pump-oxygenator that can 
embolize to the patient. In rare cases, heparin can 
also produce adverse effect such as severe throm-
bocytopenia.
Thrombin has both procoagulant and anticoagu-
lant properties.46 Apart from cleaving fibrinogen to 
fibrin, thrombin also stimulates endothelial cells to 
produce tissue plasminogen activator (t-PA), which 
is the major enzyme that cleaves plasminogen to 
plasmin; stimulates the production of nitric oxide 
and prostaglandin by endothelial cells. Thrombin in 
the presence of thrombomodulin activates protein 
C, which in the presence of protein S destroys factor 
Va and VIIIa.
Circulating thrombin is a powerful agonist and 
binds avidly to two specific thrombin receptors on 
platelets: Protease activated receptor (PAR-1) and 
glycoprotein Ib-α (GPIb-α). As extracorporeal per-
fusion continues, C5a, C5b-9, hypothermia, plate-
let activating factor (PAF), interleukin-6, cathepsin 
G, serotonin, epinephrine, eicosanoids, adenosine 
diphosphate (ADP) also activate platelets and con-
tribute to their loss and dysfunction.
The initial platelet reaction to agonists is a shape 
changes from a discoid form to an extended pseu-
dopods form, which expresses GPIb and GPIIb/IIIa 
receptors. GPIIb/IIIa receptors bind platelets to ex-
posed binding sites on surface-adsorbed fibrinogen. 
This receptor also binds plasma fibrinogen mole-
cules to form platelet aggregates. During eCP the 
circulating platelet load is reduced by dilution, ad-
hesion, aggregation, destruction, and consumption.
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Inflammatory Response
Any surgery, like a trauma, represents an aggres-
sion and therefore triggers an acute inflammatory 
response. In cardiac surgery, the foreign surfaces is 
a fundamental inciting agent of damaging effects 
of CPB, leading by the oxygenator where is the sur-
face of greatest direct contact with blood. It is next 
greater in the heat exchanger, next in filters, and 
least in tubing and reservoirs. [47]
Blood pumps, suction systems, abrupt blood ac-
celeration and deceleration, and cavitation around 
the end of the arterial cannula generate shear stres-
ses. Shear stresses damage erythrocytes, and leu-
kocytes. Hemolysis and free hemoglobin increases 
proportionally to shear stresses. Negative pressure 
of sucker systems is more damaging to erythrocytes 
than positive ones. 
For leukocytes, shear stresses not only increase 
leukocyte disruption but also increase degranulation 
and adherence and decrease aggregation, chemo-
tactic migration, and phagocytosis in nondisrupted 
leukocytes.
In cardiac surgery, the continuous recirculating of 
the heparinized blood, the duration of the surgery, 
nonendothelial surfaces of the perfusion circuit, and 
the ischemic/reperfusion time, magnifies the inflam-
matory response. 
The main blood elements involved in this acute 
defense reaction are contact and complement plas-
ma protein systems, neutrophils, monocytes, en-
dothelial cells, and platelets. These blood elements 
produce inflammatory and inhibitory cytokines, ex-
press cellular receptors that interact with specific cell 
signaling substances and other cells, and generate 
a host of vasoactive and cytotoxic substances. Nor-
mally these reactive blood elements mediate and 
regulate the inflammatory response,48 but during 
CPB this reaction is overwhelmed by the massive 
activation and recirculation of these reactive blood 
elements.
Complement 
Three pathways activate this system of plasma 
proteins, but only the classical and alternative 
pathways are involved in CPB. The complement 
system is activated at three different times during 
CPB: during blood contact with nonendothelial 
cell surfaces and wound exudate containing tissue 
factor; after protamine administration at the end 
of CPB and formation of the protamine-heparin 
complex; and after reperfusion of the ischemic, 
arrested heart.
The heparin-protamine complex activates com-
plement by the classical pathway. But, during CPB, 
the alternative pathway largely activates comple-
ment. The complement leads to the formation of 
the membrane attack complex C5b-9, the produc-
tion of powerful anaphylatoxins (C3a, C4a, and C5a) 
that increase vascular permeability, cause smooth 
muscle contraction, mediate leukocyte chemotaxis, 
facilitate neutrophil aggregation and enzyme relea-
se. C5b-9 may also activate platelets and promote 
platelet-monocyte aggregates.
C5a is the principal agonist for activating neutro-
phils and is a potent chemoattractant for neutro-
phils, monocytes, macrophages, eosinophils, baso-
phils, and microglial cells. [49]
Neutrophils
Neutrophils are strongly activated during CPB. C5a 
is a potent chemotactic protein that induces neu-
trophil chemotaxis, degranulation, and superoxide 
generation. [50] 
They migrate directionally toward areas of higher 
complement concentration, change their shape, and 
become more adhesive. Arrive at the scene of in-
flammation to begin the process of phagocytosis 
and release of cytotoxins from azurophilic granules: 
lysozyme, myeloperoxidase, cationic proteins, elasta-
se, collagenases, proteinase 3, acid hydrolases, de-
fensins, and phospholipase. Specific granules contain 
β-2 integrins, lactoferrin, lysozyme, type IV collage-
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nase, histaminase, heparanase, complement activa-
tor, alkaline phosphatase, and membrane- associa-
ted nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase.50 Circulation of these cytokines 
mediates many of the manifestations of the initially 
called “whole body inflammatory response”, now 
“systemic inflammatory response syndrome.”
Monocytes 
Are activated during CPB and have a major role in 
thrombin formation as associate with plasma tissue 
factor to rapidly accelerate the conversion of factor 
VII to factor VIIa. Are the major source of the early 
response cytokines IL-1-beta and TNF-α, IL-8, which 
induces neutrophil chemotaxis. [48]
Endothelial cells
The principal agonists for endothelial cell activation 
during CPB are thrombin, C5a, and the cytokines IL-
1-β and TNF-α.51 IL-1-β and TNF-α induce endothe-
lial cell production of the chemotactic proteins IL-8 
and MCP-1, and induce production of prostaglandin 
I2 and nitric oxide. [52] 
Platelets 
Contribute to the inflammatory by synthesis and re-
lease of eicosanoids,53 serotonin from dense granu-
les; IL-1-β; Platelet factor 4 (PF4), neutrophil-activa-
ting protein-2, IL-8, and endothelial cell neutrophil 
attractant-78; and macrophage inflammatory pro-
tein-1a, Monocyte chemoattractant protein 3 (MCP-
3), and RANTeS from α granules. [54]
Cytokines 
IL-1β, TNF-α, IL-8, MCP-1, IL-6 are the major proin-
flamatory cytokines involved in the inflammatory 
response. IL-10 is the major anti-inflammatory cyto-
kine during CPB. Proinflammatory cytokines increa-
se during CPB, but peak concentrations occur 12 to 
24 hours after CPB ends. APOe4 allele, one of the 
gene encoding apolipoprotein e, is associated with 
increased TNF-α and IL-8
The magnitude of this defense reaction during 
and after CPB is influenced by many exogenous 
factors that include the surface area of the per-
fusion circuit, the duration of blood contact with 
extravascular surfaces, the amount of unwashed 
cardiotomy suction blood returned to the patient, 
general health and preoperative organ function of 
the patient, blood loss and replacement, organ is-
chemia and reperfusion injury, sepsis, different de-
grees of hypothermia, periods of circulatory arrest, 
genetic profiles.
excluding unwashed field blood from the perfu-
sion circuit reduces admixture of high concentra-
tions of thrombin, fibrinolysins, cytokines, activated 
complement,55 and leukocytes to the perfusate. 
exclusion of these inflammatory mediators may be 
more important in reducing the amounts of vasoac-
tive and cytotoxic substances circulating within the 
body than the heparin surface coating.
Leukocyte Filtration
The role of neutrophils in the acute inflammatory 
response has led to development of leukocyte-de-
pleting filters for the CPB circuit. Consistent effi-
cacy in reducing markers of neutrophil activation 
and improvement in respiratory or renal function 
are lacking. Washing cardiotomy suction blood and 
using leukodepleted allogenic red cell and platelet 
transfusions has reduced the interest in leukocyte 
filtration. Active sequestration of leukocytes and 
platelets using a separate cell separator may have 
beneficial effects, but requires a separate inflow 
cannula and separator system.
Extracorporeal membrane oxygenation 
(ECMO)
eCMO uses modified CPB technology to provide 
prolonged respiratory or cardiorespiratory support 
to patients of all ages who have failed conven-
tional intensive care.56 Venous blood is drained 
into the eCMO circuit where it is oxygenated, car-
bon dioxide is removed and it is rewarmed before 
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being returned to the body. It can be used to 
support any patient with severe but potentially re-
versible respiratory, cardiac, or multi-organ failure 
who does not have a contraindication to limited 
heparinization.
There are two types: venoarterial (VA) and ve-
novenous (VV). The VA eCMO returns flow into a 
central artery. This flow is in addition to the nati-
ve cardiac output. VV eCMO is dependent upon 
the patient having adequate cardiac function to 
pump oxygenated blood through the systemic cir-
culation. It is used for the support of primary respi-
ratory failure and not for support of failed cardiac 
function. 
VA eCMO: used for support of cardiac and/or 
respiratory failure, Decrease preload to Right Ven-
tricle (RV), Decrease preload an increase afterload 
to Left Ventricle (LV), Coronary perfusion potentially 
hypoxic, pulmonary blood flow markedly diminis-
hed at full flow , thromboembolism risk to the sys-
temic circulation.
VV eCMO: Support of respiratory failure with sta-
ble cardiac function, No decrease in preload, De-
creased afterload to RV,  Coronaries perfused with 
well-oxygenated blood Pulmonary blood flow main-
tained with oxygenated blood, thromboembolism 
risk primarily to pulmonary circulation. [57]
Miniaturized CPB
Miniaturized CPB circuits have been developed with 
the objective of reducing the damaging effects of 
conventional CPB. It is hypothesized that mini-
mizing hemodilution and mechanical blood trau-
ma will improve outcomes. These closed circuits 
with little or no blood/air contact consist of a 
controlled vortex blood pump and a membrane 
oxygenator as the only components. There is no 
venous reservoir and no integral cardiac suction 
device. The components, including the tubing, are 
heparin coated. 
Clinical studies in patients undergoing CABG su-
ggest that use of these circuits is associated with 
fewer transfusions of blood products, less release 
of cardiac troponin, less postoperative atrial fibri-
llation, a lower prevalence of acute kidney injury, 
suppression of thrombin generation and coagulo-
fibrinolytic activation, and lower levels of IL-6 and 
SC5b-9.58
Miniaturized circuits are associated with substan-
tial reductions in neurologic injury, number of pa-
tients requiring transfusion of blood products, and 
peak cardiac troponin release.
Conclusion
CPB represent a crucial event in history of cardiac 
surgery. There are been described the determinants 
of safe perfusion, but the ideal variables of tempe-
rature, pH, Hematocrit are still controversial. Further 
understanding of the pathophysiology of the perfu-
sion system may resolve the debate.
The continuous generation of thrombin that 
overwhelms all the actual known anticoagulants is 
the cause of the thrombotic and bleeding complica-
tions associated, because produces a consumptive 
coagulopathy, which consumes coagulation fac-
tors and functional platelets. The development of 
a substance that completely inhibits the thrombin 
generation is a matter of work today.
The acute inflammatory response together with 
microembolization is responsible for most of the 
morbidity of CPB. It appears unlikely that drug coc-
ktails or indirect measures directed against specific 
mediators of this response will prove more than mil-
dly effective, given the magnitude and diversity of 
the acute inflammatory response. Miniaturized-CPB, 
micro-filters are some efforts on reduce damaging 
effects and produce more clinical benefits.
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